Thermo Fisher Scientific Inc risk profile
45 Elevated one input has moved against it
Measured 1 September 2026 from TMO's filed statements. Recomputed nightly.
45 (Elevated), driven by Competitive position at 66, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 21 | Normal | Stable | One-year price volatility — 30.3% |
| Operating pressure | 35 | Normal | Easing | Costs outgrowing revenue — -0.3 percentage points |
| Cash conversion | 27 | Normal | Worsening | Cash conversion — 1.16x |
| Leverage and coverage | 24 | Normal | Stable | Net debt to EBITDA — 2.86x |
| Competitive position | 66 | Stretched | Stable | Revenue-growth gap against peers — -30.8 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31Pfizer Inc 44
Financials, valuation and price history for Thermo Fisher Scientific Inc